hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06270459, orgStudyIdInfo id: DSRB 2023/00954, briefTitle: Telerehabilitation Robotics for Upper Limb Rehabilitation After STroke, acronym: TRUST, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-02-15, primaryCompletionDateStruct date: 2025-08-14, completionDateStruct date: 2025-08-14, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-02-21, sponsorCollaboratorsModule leadSponsor name: Tan Tock Seng Hospital, class: OTHER, collaborators name: National University Hospital, Singapore, collaborators name: Singapore General Hospital, descriptionModule briefSummary: There has been an observed decrease in motor and functional ability and non-use of the impaired limb in chronic patients. This is due to the immediate drop in intensive daily therapy (5 days per week for 3 hours/day) that is usually provided during the inpatient (acute) phase upon discharge from the hospital.In this study, the investigators plan to address the low dosage of therapy in the post-acute discharge phase for stroke survivors., conditionsModule conditions: Stroke, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: The study is a multi-site prospective clinical trial, with single-arm study design with independent assessment of outcome measures (i.e., robotic metrics, standardized outcomes, quality of life, subjective measures)., primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 54, type: ESTIMATED, armsInterventionsModule interventions name: HMAN Robot, outcomesModule primaryOutcomes measure: Compliance Rates, secondaryOutcomes measure: Fugl Meyer Motor Assessment (FMA), secondaryOutcomes measure: Action Research Arm Test (ARAT), secondaryOutcomes measure: Grip strength (KgF) measured by Digital Dynamometer (mean of 3 readings will be recorded), secondaryOutcomes measure: System Usability Scale (SUS), secondaryOutcomes measure: Intrinsic Motivation Inventory (IMI), eligibilityModule sex: ALL, minimumAge: 21 Years, maximumAge: 90 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06270446, orgStudyIdInfo id: DSRB 2019/01135, briefTitle: Community Based Rehabilitation Model After Total Knee Replacement, statusModule overallStatus: COMPLETED, startDateStruct date: 2021-01-01, primaryCompletionDateStruct date: 2022-07-01, completionDateStruct date: 2022-07-01, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-02-21, sponsorCollaboratorsModule leadSponsor name: Tan Tock Seng Hospital, class: OTHER, descriptionModule briefSummary: To investigate the clinical efficacy of community-based early stage knee replacement rehabilitation program as compared with usual care in acute hospital outpatient clinic, conditionsModule conditions: Knee Osteoarthritis, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, maskingDescription: Data analysis blinded, enrollmentInfo count: 59, type: ACTUAL, armsInterventionsModule interventions name: Community based physiotherapy, interventions name: Outpatient physiotherapy, outcomesModule primaryOutcomes measure: TUG, primaryOutcomes measure: 30 sec chair stand test, primaryOutcomes measure: Pain intensity, secondaryOutcomes measure: Knee flexion and extension, secondaryOutcomes measure: Passive range of motion, secondaryOutcomes measure: Presence of lag, otherOutcomes measure: OKS, eligibilityModule sex: ALL, minimumAge: 55 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Tan Tock Seng Hospital, city: Singapore, country: Singapore, geoPoint lat: 1.28967, lon: 103.85007, hasResults: False
protocolSection identificationModule nctId: NCT06270394, orgStudyIdInfo id: MJX, briefTitle: FAP PET/CT or PET/MR Production in the Diagnosis, Staging, and Efficacy Assessment of Malignant Tumors Application, statusModule overallStatus: SUSPENDED, startDateStruct date: 2022-04-28, primaryCompletionDateStruct date: 2023-07-28, completionDateStruct date: 2027-03-31, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-02-21, sponsorCollaboratorsModule leadSponsor name: The First Affiliated Hospital of Anhui Medical University, class: OTHER, collaborators name: National Natural Science Foundation of China, descriptionModule briefSummary: This clinical trial aims to investigate the value of fibroblast activation protein PET/CT(PET/MR) in the diagnosis, staging, and evaluation of treatment outcomes in malignant tumors. The main question it aims to answer is:Fibroblast Activation Protein PET/CT(PET/MR) whether or in which cases this assay is superior to conventional FDG examination in the diagnosis, staging, and assessment of therapeutic efficacy of malignant tumors, thinking about the reasons behind this.Investigators will screen suitable participants among patients undergoing routine FDG examination.* Participants will sign an informed consent form* Undergo 68Ga-FAPI PET/CT (PET/MR) before surgery or biopsy* Surgical resection or puncture biopsy to obtain pathologic results. Diagnosis of patients with malignant tumors at first diagnosis; clinical staging of tumors; and clinical outcomes of patients with confirmed diagnoses will be assessed after postoperative investigator follow-up.The researchers will compare the FDG exams the participants have had to determine the effectiveness of the fibroblast activating protein test., conditionsModule conditions: Malignant Tumors, conditions: Positron-Emission Tomography, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: 68Ga-Fibroblast activation protein inhibitor, outcomesModule primaryOutcomes measure: 68Ga-Fibroblast Activation Protein Inhibitor-04 Uptake in Gastrointestinal Cancer: Comparison with 18F-FDG, secondaryOutcomes measure: Utility of 68Ga-FAPI-04 PET/MRI combines 18F-FDG PET/CT in the postoperative evaluation of gastrointestinal cancers, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: FirstHAnhuiMU, city: Hefei, state: Anhui, zip: 230032, country: China, geoPoint lat: 31.86389, lon: 117.28083, hasResults: False
protocolSection identificationModule nctId: NCT06270381, orgStudyIdInfo id: UIDB/05299/2020, briefTitle: Empower-Grief: A Study on a Selective Intervention to Prevent Prolonged Grief Disorder, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-08-07, primaryCompletionDateStruct date: 2024-11-01, completionDateStruct date: 2024-11-01, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-02-21, sponsorCollaboratorsModule leadSponsor name: ISPA - Instituto Universitario de Ciencias Psicologicas, Sociais e da Vida, class: OTHER, descriptionModule briefSummary: The goal of this clinical trial is to test, through a Randomized Controlled Trial (RCT), the efficacy of a selective and short intervention based on second and third-wave cognitive-behavioral interventions (named EMPOWER) for the initial problematic grief reactions and to study potential predictors of adherence and efficacy in bereaved relatives of palliative and oncological patients. The main question is whether EMPOWER intervention is more effective than Treatment as Usual (TAU) in preventing Prolonged Grief Disorder (PGD). Participants with initial indicators of risk of developing PGD will be randomly allocated to EMPOWER and TAU. The primary outcome considered will be symptoms of PGD. The assessment also includes measures of anxiety and depression, attachment, coping, psychological flexibility, posttraumatic growth, and therapeutic alliance. Apart from screening, three assessment moments will be considered: T1: before the first session; T2: at the last session (up to twelve weeks); and T3: follow-up assessment period at 6 months after the previous assessment., conditionsModule conditions: Grief Disorder, Prolonged, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 44, type: ESTIMATED, armsInterventionsModule interventions name: EMPOWER, interventions name: Treatment as usual (TAU), outcomesModule primaryOutcomes measure: Prolonged Grief, secondaryOutcomes measure: Anxiety and depression, otherOutcomes measure: Sociodemographic data, otherOutcomes measure: Risk Assessment for Grief, otherOutcomes measure: Coping strategies, otherOutcomes measure: Adult attachment, otherOutcomes measure: Psychological inflexibility, otherOutcomes measure: Social Support, otherOutcomes measure: Therapeutic alliance, otherOutcomes measure: Posttraumatic Growth, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Unidade Local de Saúde Santa Maria, status: RECRUITING, city: Lisboa, country: Portugal, contacts name: Alexandra Coelho, PhD, role: CONTACT, phone: 919957534, email: alexandra.moura.coelho@gmail.com, geoPoint lat: 38.71667, lon: -9.13333, hasResults: False
protocolSection identificationModule nctId: NCT06270368, orgStudyIdInfo id: PREHMO, briefTitle: Children Born Preterm: Sustainable Health Monitoring, statusModule overallStatus: RECRUITING, startDateStruct date: 2020-08-05, primaryCompletionDateStruct date: 2025-08-31, completionDateStruct date: 2025-12-31, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-02-21, sponsorCollaboratorsModule leadSponsor name: Meyer Children's Hospital IRCCS, class: OTHER, collaborators name: IRCCS Fondazione Stella Maris, descriptionModule briefSummary: Children born preterm are recognized to be at higher risk of short and long term complications and a formal follow-up of infants and children born preterm is recommended by international and national scientific societies. However, in Italy as well as in Tuscany, such a follow up is not usually done, and data are not collected in a structured way. The goal of this observational study is to evaluate the association between a large number of early life exposures and health outcomes and access to care during childhood in infants born preterm. The main questions it aims to answer are: • what is the role of prenatal and perinatal factors in influencing health outcomes during childhood in preterm infants? • What is the role of prenatal and perinatal factors in influencing access to care during childhood? Participants will be asked to attend a follow-up visit for the purpose of collecting health data., conditionsModule conditions: Premature Birth, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 650, type: ESTIMATED, outcomesModule primaryOutcomes measure: Infant development, primaryOutcomes measure: Childhood development, secondaryOutcomes measure: Presence of visual or hearing impairement, secondaryOutcomes measure: Presence of asthma, secondaryOutcomes measure: Access to care, eligibilityModule sex: ALL, minimumAge: 20 Months, maximumAge: 66 Months, stdAges: CHILD, contactsLocationsModule locations facility: Azienda Ospedaliero-Universitaria Careggi (AOUC), status: RECRUITING, city: Firenze, country: Italy, contacts name: Simone Pratesi, role: CONTACT, geoPoint lat: 43.77925, lon: 11.24626, locations facility: Meyer Children's Hospital IRCCS, status: RECRUITING, city: Firenze, country: Italy, contacts name: Vieri Lastrucci, role: CONTACT, email: vieri.lastrucci@meyer.it, geoPoint lat: 43.77925, lon: 11.24626, locations facility: Azienda Ospedaliero Universitaria Pisana (AOUP), status: RECRUITING, city: Pisa, country: Italy, contacts name: Rosa Scaramuzzo, role: CONTACT, geoPoint lat: 43.70853, lon: 10.4036, locations facility: Azienda Ospedaliero Universitaria Senese (AOUS), status: RECRUITING, city: Siena, country: Italy, contacts name: Carlo Valerio Bellieni, role: CONTACT, geoPoint lat: 43.31822, lon: 11.33064, hasResults: False
protocolSection identificationModule nctId: NCT06270355, orgStudyIdInfo id: 2023-06555-01, briefTitle: Stockholm Mammography Risk Stratified Trial, acronym: SMART, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-08, primaryCompletionDateStruct date: 2028-04-08, completionDateStruct date: 2032-04-08, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Karolinska Institutet, class: OTHER, descriptionModule briefSummary: SMART is a Phase III, randomised, non-blinded screening trial. Women who consent to participate in SMART are randomised to either individualised screening or screening according to the Swedish National Breast Cancer Screening Program. Women randomised to individualised screening get their 2-year risk of breast cancer assessed and women with the highest short-term risk are offered contrast enhanced mammography and a mammogram at 12 months., conditionsModule conditions: Breast Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: SCREENING, maskingInfo masking: NONE, enrollmentInfo count: 70000, type: ESTIMATED, armsInterventionsModule interventions name: Risk based screening, outcomesModule primaryOutcomes measure: Incidence of interval cancers, secondaryOutcomes measure: Number of recalled women, otherOutcomes measure: Number of biopsies, otherOutcomes measure: Breast cancer, otherOutcomes measure: Tumor characteristics - Stage, otherOutcomes measure: Tumor characteristics - Multifocality, otherOutcomes measure: Tumor characteristics - Receptor status, otherOutcomes measure: Tumor characteristics - Proliferation, otherOutcomes measure: Cancer worry, otherOutcomes measure: Cancer anxiety, otherOutcomes measure: Side effects related to contrast enhanced mammography, otherOutcomes measure: Cost-effectiveness, otherOutcomes measure: Willingness-to-pay, eligibilityModule sex: FEMALE, minimumAge: 40 Years, maximumAge: 74 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06270342, orgStudyIdInfo id: DTMS, briefTitle: The Effect of Dual Task On Upper Extremity Functions In Multiple Sclerosis Patients, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-06-01, primaryCompletionDateStruct date: 2023-09-01, completionDateStruct date: 2023-12-15, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-02-21, sponsorCollaboratorsModule leadSponsor name: Kutahya Health Sciences University, class: OTHER, descriptionModule briefSummary: The primary aim of this study was to investigate the effect of dual tasking on upper extremity functions in individuals with multiple sclerosis (MS) and compare with healthy controls. Additionally, another aim of our study was to compare the cognitive status, quality of life, fatigue and emotional states of individuals with MS and healthy controls., conditionsModule conditions: Multiple Sclerosis, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: OTHER, enrollmentInfo count: 60, type: ACTUAL, armsInterventionsModule interventions name: dual task assessment, outcomesModule primaryOutcomes measure: The Minnesota Manual Dexterity Test, primaryOutcomes measure: Dual Task Questionnaire, primaryOutcomes measure: Edinburgh Handedness Questionnaire, primaryOutcomes measure: Expanded Disability Status Scale, primaryOutcomes measure: Brief International Cognitive Assessment Battery for Multiple Sclerosis, primaryOutcomes measure: Beck Depression Scale, primaryOutcomes measure: Fatigue Impact Scale, primaryOutcomes measure: Multiple Sclerosis Quality of Life Questionnaire-54, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Kutahya Health Sciences University, city: Kütahya, zip: 43100, country: Turkey, geoPoint lat: 39.42417, lon: 29.98333, hasResults: False
protocolSection identificationModule nctId: NCT06270329, orgStudyIdInfo id: NMTwithKOA, briefTitle: Neuromuscular Training Program in Patients With Knee OA (Osteoarthritis), acronym: OA, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-01-15, primaryCompletionDateStruct date: 2023-01-15, completionDateStruct date: 2023-06-15, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-02-21, sponsorCollaboratorsModule leadSponsor name: Kutahya Health Sciences University, class: OTHER, descriptionModule briefSummary: The aim of this study was to compare the effects of neuromuscular training program and conventional physical therapy program on pain, functional status, physical performance, balance, muscle strength and quality of life in patients with knee osteoarthritis (KOA)., conditionsModule conditions: Knee Osteoarthritis, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: randomized controlled clinical trial design, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 70, type: ACTUAL, armsInterventionsModule interventions name: Neuromuscular training program, interventions name: conventional physical therapy program, outcomesModule primaryOutcomes measure: Visual Analog Scale, primaryOutcomes measure: Western Ontario and McMasterUniversities Osteoarhritis Index, primaryOutcomes measure: Time on One Leg Standing, primaryOutcomes measure: Five Times Sit to Stand Test, primaryOutcomes measure: Manual Muscle Test, primaryOutcomes measure: Short Form, eligibilityModule sex: ALL, minimumAge: 40 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Kutahya Health Science University, city: Kütahya, zip: 43100, country: Turkey, geoPoint lat: 39.42417, lon: 29.98333, hasResults: False
protocolSection identificationModule nctId: NCT06270316, orgStudyIdInfo id: CT-AMT-191-01, briefTitle: Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disease, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-15, primaryCompletionDateStruct date: 2027-04-01, completionDateStruct date: 2027-04-29, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-02-21, sponsorCollaboratorsModule leadSponsor name: UniQure Biopharma B.V., class: INDUSTRY, descriptionModule briefSummary: This is an open-label multi-center study to evaluate safety and biomarkers of efficacy of a single dose of intravenously-administered AMT-191. The study will also include exploratory functional efficacy assessments. The plan is to investigate 2 sequential dose cohorts in 3-6 Participants per cohort. Participants will be monitored for 24 hours following AMT-191 administration then follow-up study visits will continue for 24 months, during which safety, pharmacokinetics/pharmacodynamics, biomarkers, and efficacy assessments will be performed. Participants will continue receiving their regularly scheduled enzyme replacement therapy (ERT) until they meet the criteria for withdrawal., conditionsModule conditions: Fabry Disease, designModule studyType: INTERVENTIONAL, phases: PHASE1, phases: PHASE2, designInfo allocation: NON_RANDOMIZED, interventionModel: SEQUENTIAL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 12, type: ESTIMATED, armsInterventionsModule interventions name: AMT-191, outcomesModule primaryOutcomes measure: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability], primaryOutcomes measure: Duration of Vector deoxyribonucleic acid (DNA) shedding presented in blood, saliva, feces, semen, and urine, eligibilityModule sex: MALE, minimumAge: 18 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06270290, orgStudyIdInfo id: 327648, briefTitle: The COSP-RBD Study: Concussions and Contact Sports in RBD vs Controls, acronym: COSP-RBD, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-22, primaryCompletionDateStruct date: 2025-03-30, completionDateStruct date: 2025-03-30, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-04-23, sponsorCollaboratorsModule leadSponsor name: Guy's and St Thomas' NHS Foundation Trust, class: OTHER, descriptionModule briefSummary: The goal of this observational study is to investigate concussions and contact sports practices in REM sleep behaviour disorder (RBD).The main questions it aims to answer are:* What is the proportion of patients with RBD that have a history of concussions or exposure to contact sports?* Is this proportion higher to that in control patients without a diagnosis of RBD?Participants will undergo an interview with a sleep medicine specialist to answer questions about history of concussions and contact sports practices.Researchers will compare an RBD group and a control group (without RBD) to see if the proportion of concussions and exposure to contact sports differ., conditionsModule conditions: REM Sleep Behavior Disorder, conditions: Concussion, Brain, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: RETROSPECTIVE, enrollmentInfo count: 140, type: ESTIMATED, armsInterventionsModule interventions name: Exposure to contact sports or history of concussions, outcomesModule primaryOutcomes measure: Proportion of history of contact sports practice / concussion in RBD and control participants., secondaryOutcomes measure: Differences in concussions characteristics between RBD and control participants., secondaryOutcomes measure: Demographic or clinical differences between RBD participants with and without concussions history., eligibilityModule sex: ALL, minimumAge: 50 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Guy's & St Thomas' NHS Foundation Trust, status: RECRUITING, city: London, zip: SE1 9RT, country: United Kingdom, contacts name: Gill Radcliffe, role: CONTACT, phone: 02071888070, email: gillian.radcliffe@gstt.nhs.uk, geoPoint lat: 51.50853, lon: -0.12574, hasResults: False